Through the use of our unique drug delivery technology, LiquiXR®, Tris Pharma is pioneering strategies to attack a variety of diseases. Extending our successful track record of 7 approved NDAs in just 7 years, Tris Pharma's rich pipeline of product candidates demonstrates our leadership in developing innovative drugs that meet otherwise unmet patient needs.

Lead products in development

Branded
Pipeline
Program
Commercial
Partner
Indication Approval Stage
  • EARLY
    DEVELOPMENT
  • EARLY
    CLINICAL
  • ADVANCED
    CLINICAL
  • NDA
    SUBMISSION
TRN-110 Tris Pediatric & Adult ADHD

TRN-124 Tris Cough & Cold

TRN-125 Aytu Bioscience Cough & Cold

TRN-167 Undisclosed Rare CNS

TRN-123 Tris Cough & Cold

TRN-152 Tris Pain

TRN-148 Tris Pediatric ADHD

TRN-176 Tris Pediatric & Adult ADHD

TRN-TBD Tris Anti-infective

Indication:

Pediatric & Adult ADHD


Commercial Partner:

Tris

Approval:

NDA Submission

Indication:

Cough & Cold


Commercial Partner:

Tris

Approval:

NDA Submission

Indication:

Cough & Cold


Commercial Partner:

Aytu Bioscience

Approval:

NDA Submission

Indication:

Rare CNS


Commercial Partner:

Undisclosed

Approval:

Early Clinical

Indication:

Cough & Cold


Commercial Partner:

Tris

Approval:

Early Clinical

Indication:

Pain


Commercial Partner:

Tris

Approval:

Early Clinical

Indication:

Pediatric ADHD


Commercial Partner:

Tris

Approval:

Early Development

Indication:

Pediatric & Adult ADHD


Commercial Partner:

Tris

Approval:

Early Development

Indication:

Anti-infective


Commercial Partner:

Tris

Approval:

Early Development

ADHD, attention deficit hyperactivity disorder; CNS, central nervous system; NDA, new drug application.

Contact us

Interested in learning more about our products, pipeline, and partnerships?